Abstract Tumour vaccines are designed to stimulate the host’s immune system against existing tumours or tumour recurrence. However, individual differences, tumour heterogeneity and side effects hinder the applications of current tumour vaccines and require the development of personalized cancer vaccines. To overcome these challenges, we engineered pyroptotic vesicles—extracellular vesicles formed during tumour cell pyroptosis—as a tumour vaccine platform.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Fanyi
Contact Fanyi, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack